RoosterBio has announced the launch of the Regenerative Medicine (RM) industry’s first xeno-free (XF) hMSC cell banks to advance and simplify stem cell biomanufacturing. By incorporating XF starting materials at early stages, RM scientists can perform more clinically relevant work, resulting in an expedited path towards clinical testing programs. Due of the importance of this announcement, I followed up with Dr. Priya Baraniak, Director of BD & Strategic Marketing at RoosterBio, to further explore details of the launch. [Read more…]
RoosterBio Launches Xeno-Free hMSC Cell Banks to Advance Stem Cell Biomanufacturing
RoosterBio Launches the Regenerative Medicine Industry’s First Xeno-Free hMSC Cell Banks to Advance and Simplify Stem Cell Biomanufacturing
FREDERICK, MARYLAND, May 04, 2017–At a CAGR of 23.2% and estimated revenue of $68B by 2020, the Regenerative Medicine (“RM”) industry continues to call for new tools designed to accelerate this aggressive growth. Based on strong RM market demand, RoosterBio Inc today announces the launch of xeno-free (“XF”) human bone-marrow derived mesenchymal stem/stromal cell (hMSC) products.
GenCure, StemBioSys Forge Stem Cell Product Manufacturing Agreement
GenCure will be exclusive producer for StemBioSys-developed regenerative medicine products
January 30, 2017, SAN ANTONIO – GenCure, a subsidiary of San Antonio-based biotech BioBridge Global, has entered a development and manufacturing agreement with stem cell technology developer StemBioSys Inc. of San Antonio. [Read more…]
RoosterBio Releases Universal Bioprocess Bags to Streamline Closed System Stem Cell Production
RoosterBio is an innovative mesenchymal stem cell (MSC) company that is focusing on democratizing stem cell manufacturing and ushering in a new era of regenerative medicine. 2016 has been a massive year for the company, as it recently announced a collaboration with BioBridge Global, as well as a co-branding partnership with the global filtration, separation and purification leader, Pall Corporation. [Read more…]
Pall Corporation and RoosterBio to Co-Market Mesenchymal Stem/Stromal Cells and Bioreactors
The agreement will encompass a co-development and marketing partnership.
OCTOBER 05, 2016 –Pall Corporation, a global leader in bioprocess equipment and disposables, announced the signing of a commercial collaboration agreement with RoosterBio Inc, an innovative adult stem cell technology company. The agreement will encompass a co-development and marketing partnership, delivering complete solutions for industrial-scale bioreactor expansion of human Mesenchymal Stem/Stromal Cells (hMSCs). [Read more…]
